

Attorney's Docket No. 046562/274660

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Fraser <i>et al.</i>	Confirmation No.:	1508
Appl. No.:	10/805,977	Group Art Unit:	1614
Filed:	March 22, 2004	Examiner:	Graffeo, Michel
For:	METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING $\alpha_2\delta$ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)**

Sir:

Attached is a list of documents on form PTO-1449 along with a copy of any cited foreign patent documents and non-patent literature document in accordance with 37 CFR 1.98(a)(2). Also enclosed is a translation or a concise explanation of each non-English language document.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

The Commissioner is authorized to charge the \$180.00 fee specified in 37 C.F.R. § 1.17(p) and any additional fee, or credit any refund, to our Deposit Account No. 16-0605.

In re: Fraser *et al.*
Appl. No.: 10/805,977
Filed: March 22, 2004
Page 2

Respectfully submitted,

/edward r. ergenzinger/

Edward R. Ergenzinger
Registration No. 47,549

CUSTOMER No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON May 4, 2007.

Substitute for form 1449/PTO (Revised 07/2005)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/805,977
		Filing Date	March 22, 2004
		First Named Inventor	Fraser <i>et al.</i>
		Group Art Unit	1614
		Examiner Name	Graffeo, Michel
Sheet	1	of	1
		Attorney Docket Number	046562/274660
OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	52	BRYANS, et al., "Identification of Novel Ligands for the Gabapentin Binding Site on the alpha2-delta Subunit of a Calcium Channel and Their Evaluation as Anticonvulsant Agents," <i>Journal of Medicinal Chemistry</i> , 1998, pp. 1838-1845, Vol. 41.	
	53	BRYANS, et al., "3-Substituted GABA Analogs with Central Nervous System Activity: A Review," <i>Med Res Rev</i> 19, 1999, pp. 149-177.	
	54	OSOL A [Editor], "Structure-Activity Relationship and Drug Design," <i>Remington's Pharmaceutical Sciences</i> (Sixteenth Edition), Mack Publishing, 1980, pp. 420-435.	
	55	GARNETT et al., "Clinical Aspects of the Overactive Bladder and Detrusor Overactivity," <i>Scand J Urol Nephrol Suppl.</i> , 2002, pp. 65-71, Vol. 210.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.